Gilead Sciences, Inc.: EPS $2.55 vs $2.19 expected; revenue $8.30B vs $7.80B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 2.55 | 2.19 | +16.4% | 2.47 |
| Revenue (USD bn) | 8.30 | 7.80 | +6.4% | 7.77 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Q3 FY2026 | 2.55 | 2.19 | +16.4% | 8.30 | 7.80 | +6.4% |
| Aug 4, 2026 | Q2 FY2026 | −6.75 | −7.25 | +6.9% | 7.80 | 7.40 | +5.5% |
| May 7, 2026 | Q1 FY2026 | 2.03 | 1.91 | +6.3% | 6.96 | 6.91 | +0.7% |
| Feb 10, 2026 | Q4 FY2025 | 1.86 | 1.81 | +2.8% | 7.93 | 7.69 | +3.1% |
| Oct 30, 2025 | Q3 FY2025 | 2.47 | 2.13 | +16.0% | 7.77 | 7.45 | +4.3% |
| Aug 7, 2025 | Q2 FY2025 | 2.01 | 1.96 | +2.6% | 7.08 | 6.98 | +1.4% |
| Apr 24, 2025 | Q1 FY2025 | 1.81 | 1.78 | +1.7% | 6.67 | 6.81 | −2.1% |
| Feb 11, 2025 | Q4 FY2024 | 1.90 | 1.74 | +9.2% | 7.57 | 7.15 | +5.8% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Gilead Sciences, Inc. results: EPS $2.55 vs $2.19 expected; revenue $8.30B vs $7.80B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 16.4%; revenue above the estimate by 6.4%.
Revenue was up 6.8% from $7.77 billion a year earlier (Q3 FY2025). EPS was up 3.2% from $2.47 a year earlier. On its record, EPS topped analysts' estimates in 7 of 7 earlier comparable reports.
What the results mean
The results reflect revenue growth at Gilead Sciences, but the available information does not identify how individual therapeutic areas contributed. The business rests on a portfolio spanning treatments for human immunodeficiency virus, liver diseases, cancer, and cell therapy.
The significance of this portfolio lies in the range of medical needs it serves. Understanding what growth means for the business requires clarity on which products are driving demand and how their contributions are distributed across therapeutic areas and markets.
Gilead’s business development involves discovering, developing, and commercializing medicines, alongside collaborations to advance its therapeutic pipeline. The relationship between marketed medicines and research and development spending is therefore an important lens for understanding profitability.
What to watch on the earnings call: The earnings call merits attention to management’s explanation of revenue growth and demand across treatments for human immunodeficiency virus, liver diseases, cancer, and cell therapy. Discussion of margins, research and development spending, and the role of partnerships in advancing investigational medicines will also be relevant.
For the full analysis of Gilead Sciences, Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.